Research programme: tissue factor/factor VIIa complex inhibitors - BioCryst/Sunol Molecular

Drug Profile

Research programme: tissue factor/factor VIIa complex inhibitors - BioCryst/Sunol Molecular

Alternative Names: BCX 3607; BCX 3891

Latest Information Update: 02 Apr 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator BioCryst Pharmaceuticals; Sunol Molecular Corporation
  • Developer BioCryst Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Factor VIIa inhibitors; Thromboplastin inhibitors; Tissue factor-factor VIIa complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Coronary disorders; Thrombosis

Most Recent Events

  • 31 Mar 2005 Data presented at the 229th American Chemical Society National Meeting (229th-ACS-2005) have been added to the Thromboses pharmacodynamics section
  • 01 Sep 2004 Preclinical trials in Cancer in USA (PO)
  • 09 May 2001 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top